Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss.
Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo.
https://pubmed.ncbi.nlm.nih.gov/36089112/
Related Content
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
VIEW RESOURCEIntroduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCE